Multiple System Atrophy (MSA)
Patient Condition
MSA-P, progressive parkinsonism for 28 months with poor L-dopa response. Severe nocturnal stridor, orthostatic hypotension, and rapidly progressive cognitive decline. UMSARS-I 26, UMSARS-II 32, SCOPA-AUT 24, MoCA 19. Enrolled in anti-inflammatory immunotherapy trial.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| enrollment assessment | ||
| immunotherapy | ||
| follow-up management |
Treatment Outcome
| before | UMSARS-I 26 points, UMSARS-II 32 points, MoCA 19 points, CSF NfL 95pg/mL, severe nocturnal wheezing |
|---|---|
| after | UMSARS-I improved to 24 points, UMSARS-II improved to 29 points, MoCA stabilized at 19 points, CSF NfL dropped to 72pg/mL (24% decrease), and night wheezing decreased |
| highlight | Anti-IL-1 immunotherapy effectively suppressed neuroinflammatory reactions, significantly reduced NfL, improved night wheezing through CPAP combined immunotherapy, and significantly improved motor function scores |